Abstract 5196: CD47 Blockade potentiates immunotherapy of durvalumab against cutaneous T cell lymphoma

MLA

Zhen Han, et al. “Abstract 5196: CD47 Blockade Potentiates Immunotherapy of Durvalumab against Cutaneous T Cell Lymphoma.” Cancer Research, vol. 82, June 2022, p. 5196. EBSCOhost, https://doi.org/10.1158/1538-7445.am2022-5196.

APA

Zhen Han, Mingye Feng, Xiwei Wu, Chingyu Su, Yate-Ching Yuan, Hanjun Qin, James F. Sanchez, Jasmine Zain, Steven T. Rosen, & Christiane Querfeld. (2022). Abstract 5196: CD47 Blockade potentiates immunotherapy of durvalumab against cutaneous T cell lymphoma. Cancer Research, 82, 5196. https://doi.org/10.1158/1538-7445.am2022-5196

Chicago

Zhen Han, Mingye Feng, Xiwei Wu, Chingyu Su, Yate-Ching Yuan, Hanjun Qin, James F. Sanchez, Jasmine Zain, Steven T. Rosen, and Christiane Querfeld. 2022. “Abstract 5196: CD47 Blockade Potentiates Immunotherapy of Durvalumab against Cutaneous T Cell Lymphoma.” Cancer Research 82 (June): 5196. doi:10.1158/1538-7445.am2022-5196.